Zhejiang Hisun Pharmaceutical Hits Day High with Strong 5.2% Intraday Surge

Zhejiang Hisun Pharmaceutical Co., Ltd. has experienced a notable surge in its stock performance, gaining 5.2% on July 13, 2026. The stock reached an intraday high of CNY 11.71, reflecting a strong day of trading activity. This performance stands in contrast to the broader market, as the China Shanghai Composite index declined by 2.06% on the same day. Over the past week, Zhejiang Hisun has shown a positive trend with a 3.47% increase, while its one-month performance has been even more impressive at 13.3%. However, the stock has faced challenges over the longer term, with a year-to-date performance of 14.56%, contrasting with a decline of 1.39% in the China Shanghai Composite. Key financial metrics indicate that Zhejiang Hisun maintains a return on equity of 5.96% and a price-to-book ratio of 1.47, suggesting an attractive valuation. The company also boasts a high dividend yield of 2.1%, further enhancing its financial profile. As a large-cap player in the pharmaceuticals and biotechnology sector, Zhejiang Hisun continues to navigate a complex market landscape.